KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Operating Leases: 2020-2025

Historic Operating Leases for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to $6.2 million.

  • Aurinia Pharmaceuticals' Operating Leases fell 11.38% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year decrease of 11.38%. This contributed to the annual value of $5.7 million for FY2024, which is 12.05% down from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Operating Leases stood at $6.2 million, which was down 3.21% from $6.4 million recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Operating Leases registered a high of $8.9 million during Q2 2021, and its lowest value of $5.7 million during Q4 2024.
  • For the 3-year period, Aurinia Pharmaceuticals' Operating Leases averaged around $6.9 million, with its median value being $7.0 million (2024).
  • Data for Aurinia Pharmaceuticals' Operating Leases shows a maximum YoY decreased of 12.05% (in 2024) over the last 5 years.
  • Aurinia Pharmaceuticals' Operating Leases (Quarterly) stood at $7.7 million in 2021, then declined by 6.87% to $7.2 million in 2022, then decreased by 8.70% to $6.5 million in 2023, then decreased by 12.05% to $5.7 million in 2024, then decreased by 11.38% to $6.2 million in 2025.
  • Its Operating Leases stands at $6.2 million for Q3 2025, versus $6.4 million for Q2 2025 and $6.6 million for Q1 2025.